AIDS.gov Blog Update

AIDS.gov Blog Update
FDA Safety Communication: Reducing the Risk of Hepatitis B Reactivation in Patients Using Two Immune-Suppressing and Anti-Cancer Drugs

AIDS.gov Blog Update

U.S. Dept. of Health & Human Services sent this bulletin at 10/21/2013 12:49 PM EDT AIDS.gov Blog for U.S. Dept. of Health & Human Services.
This information has recently been updated, and is now available.

FDA Safety Communication: Reducing the Risk of Hepatitis B Reactivation in Patients Using Two Immune-Suppressing and Anti-Cancer Drugs

10/21/2013 12:30 PM EDT

On September 25, 2013, the FDA issued a Drug Safety Communication announcing that the FDA has approved changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to add new Boxed Warning information about the risk of reactivation of hepatitis B virus (HBV) infection. The revised labels also will...
FDA Safety Communication: Reducing the Risk of Hepatitis B Reactivation in Patients Using Two Immune-Suppressing and Anti-Cancer Drugs